FDA-cleared IVD could replace scans There has been a significant amount of activity in recent weeks as it concerns tests to detect Alzheimer’s disease. Clinical labs and neuropathologists will want to keep a close eye on Alzheimer’s-related progress throughout the rest of 2025. Perhaps most significantly, Fujirebio made headlines with the Food and Drug Administration’s […]
News Briefs on Alzheimer’s Detection
- By Scott Wallask
- > From the Volume XXXII, No. 9 - June 23, 2025 Issue
- Tags: AD-Detect, Alzheimer’s disease, amyloid pathology, anti-amyloid therapy, arup laboratories, Aβ 42/40 ratio, composite risk score, CSF test, Eli Lilly, FDA Clearance, Food and Drug Administration, Fujirebio, genetic data, immunoassay, in vitro diagnostics, IVD, laboratory-developed test, ldt, Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, mass spectrometry, neurology, neuropathologist, PET scan, protein markers, pTau-217, Quest Diagnostics
